Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,313.00

Eli Lilly and Company (NYSE:LLY) had its price objective boosted by research analysts at Morgan Stanley from $1,290.00 to $1,313.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target would suggest a potential upside of 26.87% from the stock’s previous close.

A number of other research analysts have also commented on LLY. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday. Berenberg Bank raised their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a report on Tuesday, December 2nd. Scotiabank assumed coverage on Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective for the company. CICC Research lifted their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Finally, National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a report on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,194.92.

Eli Lilly and Company Stock Performance

LLY traded down $72.18 during trading on Thursday, hitting $1,034.94. 4,097,211 shares of the stock were exchanged, compared to its average volume of 3,262,525. The firm has a market capitalization of $978.41 billion, a P/E ratio of 50.60, a PEG ratio of 0.76 and a beta of 0.39. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The stock has a fifty day moving average price of $1,054.31 and a two-hundred day moving average price of $895.30. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period last year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. OneAscent Wealth Management LLC raised its position in Eli Lilly and Company by 32.0% during the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after acquiring an additional 87 shares during the last quarter. Sax Wealth Advisors LLC raised its position in Eli Lilly and Company by 14.3% during the second quarter. Sax Wealth Advisors LLC now owns 689 shares of the company’s stock worth $537,000 after acquiring an additional 86 shares during the last quarter. Finally, Lattice Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 19.6% in the second quarter. Lattice Capital Management LLC now owns 1,218 shares of the company’s stock valued at $949,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 outlook — Lilly topped revenue and EPS estimates on surging sales of Mounjaro and Zepbound and gave upbeat 2026 guidance that underpinned the recent rally. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Analysts remain constructive — at least one analyst kept an outperform rating and raised the price target (to $1,300), signaling continued confidence in Lilly’s multi‑year growth runway. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Execution and capacity expansion support volume growth — MarketBeat’s sector coverage highlights Lilly’s manufacturing build‑out and vial strategy that helped offset U.S. pricing pressure by driving a big volume increase. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Neutral Sentiment: Ongoing capital investment — Lilly announced sizable new manufacturing spending (e.g., a $3.5B Pennsylvania facility), which supports longer‑term supply but is near‑term capex intensive. Eli Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Pipeline and M&A activity diversify long‑term upside — deals (e.g., hearing‑loss and other collaborations) broaden optionality beyond GLP‑1s but will take time to materialize. Eli Lilly Is Getting Into the Hearing Loss Market
• Negative Sentiment: New low‑price competitor copy accelerates pricing fears — telehealth firm Hims & Hers announced a $49 copy of Wegovy, stoking concerns that cheaper entrants and pricing pressure could erode margins and force faster price competition across the GLP‑1 category. That news is a near‑term catalyst for the pullback. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Profit‑taking and volatility after a huge run — after the stock surged on the beat and guidance (reclaiming ~$1T market cap), some investors are locking gains; analysts and outlets warn a pullback is possible given the stock’s run and valuation sensitivity to GLP‑1 pricing assumptions. Why Eli Lilly Stock Just Dropped

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.